SG11201700956VA - Indoles for use in influenza virus infection - Google Patents

Indoles for use in influenza virus infection

Info

Publication number
SG11201700956VA
SG11201700956VA SG11201700956VA SG11201700956VA SG11201700956VA SG 11201700956V A SG11201700956V A SG 11201700956VA SG 11201700956V A SG11201700956V A SG 11201700956VA SG 11201700956V A SG11201700956V A SG 11201700956VA SG 11201700956V A SG11201700956V A SG 11201700956VA
Authority
SG
Singapore
Prior art keywords
indoles
influenza virus
virus infection
infection
influenza
Prior art date
Application number
SG11201700956VA
Other languages
English (en)
Inventor
Tim Hugo Maria Jonckers
Pierre Jean-Marie Bernard Raboisson
Jérôme Emile Georges Guillemont
Gowan David Craig Mc
Werner Constant Johan Embrechts
Ludwig Paul Cooymans
Antoine Benjamin Michaut
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of SG11201700956VA publication Critical patent/SG11201700956VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201700956VA 2014-08-08 2015-08-07 Indoles for use in influenza virus infection SG11201700956VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14180331 2014-08-08
PCT/EP2015/068257 WO2016020526A1 (en) 2014-08-08 2015-08-07 Indoles for use in influenza virus infection

Publications (1)

Publication Number Publication Date
SG11201700956VA true SG11201700956VA (en) 2017-03-30

Family

ID=51298610

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201700956VA SG11201700956VA (en) 2014-08-08 2015-08-07 Indoles for use in influenza virus infection

Country Status (18)

Country Link
US (1) US10597390B2 (enExample)
EP (1) EP3177609A1 (enExample)
JP (1) JP6577570B2 (enExample)
KR (1) KR102488479B1 (enExample)
CN (1) CN106573920B (enExample)
AU (1) AU2015298876B2 (enExample)
BR (1) BR112017002370B1 (enExample)
CA (1) CA2954751C (enExample)
CL (1) CL2017000309A1 (enExample)
EA (1) EA201790266A1 (enExample)
IL (1) IL250408B (enExample)
MA (1) MA40547A (enExample)
MX (1) MX381488B (enExample)
PH (1) PH12017500207B1 (enExample)
SG (1) SG11201700956VA (enExample)
UA (1) UA124609C2 (enExample)
WO (1) WO2016020526A1 (enExample)
ZA (1) ZA201700952B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201405826RA (en) 2009-06-17 2014-12-30 Vertex Pharma Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
CN106573920B (zh) 2014-08-08 2020-11-10 爱尔兰詹森科学公司 用于在流感病毒感染中使用的吲哚
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated インフルエンザウイルスの複製の阻害剤を調製する方法
AU2016368317B2 (en) 2015-12-09 2019-05-23 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
KR20180099839A (ko) * 2016-01-07 2018-09-05 얀센 사이언시즈 아일랜드 유씨 인플루엔자 바이러스 감염에서 사용하기 위한 작용화된 펜탄산
WO2017133670A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
CN107759571B (zh) * 2016-08-16 2021-03-02 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
CN109641868B (zh) * 2016-08-30 2021-12-03 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
CA3035680C (en) * 2016-09-05 2023-05-02 Jian Xiong Anti-influenza virus pyrimidine derivatives
US10987354B2 (en) 2016-12-15 2021-04-27 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
JP7299837B2 (ja) 2016-12-23 2023-06-28 アクイナ ファーマシューティカルズ, インコーポレイテッド 化合物、組成物、および使用方法
WO2018127096A1 (en) 2017-01-05 2018-07-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
CN110446711B (zh) 2017-03-02 2022-02-15 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
CN108727369B (zh) * 2017-04-25 2023-06-09 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
KR102484804B1 (ko) * 2018-03-05 2023-01-04 광둥 레이노벤트 바이오테크 컴퍼니 리미티드 이미다졸계 화합물의 결정 형태, 염 형태 및 그의 제조 방법
JP7450017B2 (ja) * 2019-07-22 2024-03-14 広東衆生睿創生物科技有限公司 ピリミジン誘導体の優位な塩形およびその結晶形
CN113045475A (zh) * 2019-12-27 2021-06-29 上海泓博智源医药股份有限公司 一种5-溴-7-甲基吲哚的制备方法
AU2021313150A1 (en) 2020-07-20 2023-03-16 Nido Biosciences, Inc. Indole compounds as androgen receptor modulators
CN114195773B (zh) * 2020-09-18 2024-04-26 广东东阳光药业股份有限公司 取代的嘧啶哌嗪化合物的制备方法
PE20251586A1 (es) * 2022-10-12 2025-06-16 Maze Therapeutics Inc Inhibidores del miembro 19 de la familia de portadores de solutos 6a (slc6a19) y metodos de uso de los mismos

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005027825D1 (de) 2004-03-30 2011-06-16 Vertex Pharma Als inhibitoren von jak und anderen proteinkinasen geeignete azaindole
EP2537849A3 (en) 2006-01-17 2013-04-03 Vertex Pharmaceuticals, Inc. Azaindoles useful as inhibitors of janus kinases
SG10201405826RA (en) * 2009-06-17 2014-12-30 Vertex Pharma Inhibitors of influenza viruses replication
US9326987B2 (en) * 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
CA2822062A1 (en) * 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
RU2013132681A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
UA118010C2 (uk) * 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP2763990B1 (en) 2011-09-01 2017-02-22 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
EP2858984A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Inc. Inhibitors of influenza viruses replication
PT3068776T (pt) 2013-11-13 2019-08-26 Vertex Pharma Inibidores da replicação de vírus da gripe
CN106573920B (zh) 2014-08-08 2020-11-10 爱尔兰詹森科学公司 用于在流感病毒感染中使用的吲哚
UY36255A (es) 2014-08-08 2016-01-29 Bayer Cropscience Ag Compuestos sustituidos por halógeno novedosos
UY36249A (es) 2014-08-08 2016-01-29 Bayer Cropscience Ag Compuestos sustituidos con halógeno novedosos
CN104592038A (zh) 2015-01-12 2015-05-06 烟台万润精细化工股份有限公司 一种5,5-二甲基-1,3-环己二胺的制备方法

Also Published As

Publication number Publication date
BR112017002370A2 (pt) 2017-12-05
EA201790266A1 (ru) 2017-06-30
ZA201700952B (en) 2018-12-19
KR20170039275A (ko) 2017-04-10
CL2017000309A1 (es) 2017-08-18
WO2016020526A1 (en) 2016-02-11
JP2017523225A (ja) 2017-08-17
IL250408B (en) 2020-08-31
AU2015298876B2 (en) 2020-02-13
UA124609C2 (uk) 2021-10-20
AU2015298876A1 (en) 2017-02-02
BR112017002370B1 (pt) 2022-11-22
CN106573920A (zh) 2017-04-19
CA2954751A1 (en) 2016-02-11
US10597390B2 (en) 2020-03-24
PH12017500207A1 (en) 2017-07-10
KR102488479B1 (ko) 2023-01-12
JP6577570B2 (ja) 2019-09-18
CA2954751C (en) 2023-01-17
PH12017500207B1 (en) 2017-07-10
IL250408A0 (en) 2017-03-30
MX381488B (es) 2025-03-12
MA40547A (fr) 2017-06-14
US20170226102A1 (en) 2017-08-10
CN106573920B (zh) 2020-11-10
MX2017001752A (es) 2018-02-08
EP3177609A1 (en) 2017-06-14

Similar Documents

Publication Publication Date Title
ZA201700952B (en) Indoles for use in influenza virus infection
ZA201701643B (en) Pyrrolopyrimidines for use in influenza virus infection
ZA201700165B (en) Influenza virus vaccines and uses thereof
GB201405834D0 (en) Oncolytic virus
GB201410971D0 (en) Vaccine
GB201406608D0 (en) Virus
LT3380467T (lt) Heterocikliniai indolai, skirti naudoti gripo viruso infekcijų atveju
SG11201610443WA (en) Influenza virus vaccines and uses thereof
PL3185899T3 (pl) Wzmocniona szczepionka wektorowa-hvt przeciwko nd-ibd
LT3405466T (lt) Arilu pakeistieji pirimidinai, skirti naudoti gripo viruso infekcijos atveju
SG11201701256RA (en) Vaccine compositions against dengue virus diseases
SG11201701279VA (en) Alkylated influenza vaccines
IL247185B (en) Tilapia virus vaccines
EP3218470A4 (en) Live attenuated vaccines for influenza viruses
GB201419572D0 (en) Virus
LT3155004T (lt) Vakcina, skirta asmeniui su sutrikusiu imunitetu
HUE053284T2 (hu) Vakcina
GB201417214D0 (en) Vaccine
GB201406628D0 (en) Vaccine
IL249705B (en) Influenza virus vaccines and their uses
IL249704A0 (en) Influenza virus vaccines and their uses
GB201406470D0 (en) Virus
GB201403582D0 (en) Virus
HK1236965A1 (en) Influenza virus vaccines and uses thereof
GB201408046D0 (en) Virus preparations